Transcenta is a fully integrated biotherapeutics company focused on discovering, developing, and manufacturing novel biologics. The company utilizes proprietary platforms, including Immune Tolerance Breaking Technology, to generate differentiated antibody candidates for clinical development. By integrating discovery, translational research, process development, and manufacturing, Transcenta aims to deliver affordable, advanced biologic treatments to patients globally.
Funding
Funding not disclosed
LAFounders
Product
Problem
The development of antibody-based therapeutics is often hindered by challenges in druggability and biological profile, leading to high costs and lengthy timelines for bringing new therapies to market. Traditional antibody generation methods may not effectively address immune tolerance, limiting the potential for creating differentiated and affordable biologics.
Solution
Transcenta is a biotherapeutics company that leverages Immune Tolerance Breaking Technology to develop antibody-based therapeutics with enhanced druggability and differentiated biological profiles. Their approach streamlines the discovery, translational research, process development, clinical development, and manufacturing stages, significantly reducing the time and costs associated with bringing novel biologics to market. Transcenta employs both classical fed-batch and perfusion-based continuous bioprocessing technologies to accelerate process development and reduce manufacturing expenses. The company's global clinical development centers and regulatory teams possess extensive knowledge and experience in designing and executing clinical trials across all stages.
Target Audience
Transcenta's primary customers are patients in need of differentiated and affordable biologics, as well as pharmaceutical companies seeking strategic collaborations for biologics development and manufacturing.
Features
- Antibody generation platform based on Immune Tolerance Breaking Technology
- Capabilities in discovery, translational research, process development, clinical development, and manufacturing
- Both classical fed-batch and perfusion-based continuous bioprocessing technologies
- Flexible modular manufacturing facility
- Global clinical development centers and regulatory teams
- Pipeline of 14 products, including Osemitamab (TST001), TST002, and TST003